Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Verenium Reports Financial Results for the Second Quarter 2010

      - Company reports healthy product revenue growth and a decrease in operating expenses -


      News provided by

      Verenium Corporation

      Aug 09, 2010, 04:00 ET

      Share this article

      Share this article


      CAMBRIDGE, Mass., Aug. 9 /PRNewswire-FirstCall/ -- Verenium Corporation (Nasdaq: VRNM), a pioneer in the development and commercialization of high-performance industrial enzyme solutions, today reported financial results for the second quarter of 2010.  The Company also provided a summary of recent highlights and financial guidance for 2010.

      "This has been a transformational quarter for Verenium. The transaction we announced with BP around the sale of our cellulosic biofuels business firmly positions us to focus our capital and human resources on the continued development of a leading industrial biotechnology and commercial enzymes business addressing lucrative, growing markets," said Carlos A. Riva, President and Chief Executive Officer of Verenium. "I'm pleased with the progress we've seen across the business over the last quarter, notably, growing product revenues and continued successful efforts to aggressively manage expenses."

      Company Highlights

      Since the beginning of 2010, Verenium has made significant progress in several important areas, including:

      Enzymes

      • Increased total product revenue by 27% for the second quarter of 2010 compared to the same period in 2009 and 15% compared to the first quarter or 2010;
      • Increased product gross margin dollars by 46% for the second quarter of 2010 as compared to the same period in 2009;
      • Increased Phyzyme revenue on both a year-over-year and sequential basis showing positive momentum versus the challenging environment of the second quarter of 2009 as a result of the impact of the recession on poultry producers;
      • Improved revenue mix from increasing sales of Company's newer enzymes including Fuelzyme, Xylathin, Veretase and Purifine;
      • Continued to gain traction with Purifine at commercial-scale with increased interest from some of the world's leading oilseed producers;
      • Advanced two pipeline product candidates into the regulatory phase; and
      • Promoted Janet Roemer to President and Chief Operating Officer of Verenium's Enzymes business.

      Biofuels

      • Announced an agreement with BP Biofuels North America to acquire Verenium's cellulosic biofuels business, including the Company's facilities in Jennings, LA and San Diego, CA for $98.3 million, subject to adjustment, and anticipate a successful transaction close by the end of August;
      • Negotiated an extension of the Galaxy joint development agreement with BP in which BP will pay Verenium an initial cash payment of approximately $1.4 million and a $5 million monthly reimbursement rate (paid in semi-monthly cash payments of $2.5 million) for the continued performance of Verenium's obligations until the close of the cellulosic biofuels business acquisition by BP; and
      • Awarded an additional $4.9 million from the U.S. Department of Energy (DOE) to fund activities at the Company's demonstration-scale facility in Jennings, Louisiana.

      Financial Results

      Total revenues for the second quarter and six months ended June 30, 2010 were $20.0 million and $33.0 million, respectively, compared to $16.3 million and $30.7 million for the same periods in the prior year, with product revenues representing more than 60 percent of total revenues in both periods. Product revenues for the second quarter and six months ended June 30, 2010 increased to $13.3 million and $24.9 million, respectively, compared to $10.5 million and $21.1 million for same periods in the prior year, primarily due to an increase in Phyzyme profit share from Danisco, as well as an increase in revenues from Veretase and Xylathin enzymes, which continued to gain acceptance in the grain ethanol markets, and Purifine enzyme for the soybean oil processing market. Fuelzyme revenues returned to levels achieved in the first quarter of 2009, indicating recovery in the corn ethanol market.

      Product gross margin dollars increased to $4.5 million in the second quarter ended June 30, 2010, versus $3.0 million for the same period in the prior year, primarily due to improved fixed costs leverage on higher revenue, partially offset by unfavorable manufacturing yields and manufacturing constraints compared to the prior year, resulting from increased demand and expansion of product mix.

      Excluding cost of product revenues, total operating expenses decreased $6.5 million to $20.5 million (including share-based compensation of $0.3 million) for the three months ended June 30, 2010 from $27.0 million (including share-based compensation of $2.6 million) for the three months ended June 30, 2009 and decreased from $54.0 million (including share-based compensation of $5.1 million) for the six months ended June 30, 2009, to $45.2 million (including share-based compensation of $0.8 million) for the six months ended June 30, 2010.  Excluding the impact of share-based compensation, total operating expenses decreased $4.3 million and $4.5 million for the three and six months ended June 30, 2010 as compared to the same period in 2009 primarily due to a $3.0 million and $3.8 million decrease in expenses related to Vercipia Biofuels, the Company's jointly owned special purpose entity with BP, which was included in the Company's consolidated results of operations during 2009.  Effective for 2010, the results of operations for Vercipia are excluded from the Company's consolidated results due to the deconsolidation based upon authoritative new accounting guidance.  This decrease in expenses was partially offset by increases in expenses related to the Company's ongoing demonstration-scale facility optimization efforts.

      Total operating expenses include gross expenses incurred to support ongoing development related to the Company's Galaxy joint venture with BP, which continues to be consolidated in the Company's financial statements.  BP's share of the total operating expenses of the joint ventures was $7.7 million and $15.2 million for the three and six months ended June 30, 2010 and is included below operating expenses as "Loss attributed to non-controlling interest in consolidated entities" on the Company's Consolidated Income Statement.  On a non-GAAP basis, net of BP's share of expenses, pro forma net operating expenses decreased as compared to prior periods, reflecting the cost sharing and the Company's expense minimization efforts.

      Interest expense related almost exclusively to the cash and non-cash interest expense from the Company's convertible debt instruments.  Of total net interest expense for the second quarter and six months ended June 30, 2010, $0.5 million and $0.9 million, respectively represents non-cash interest expense related to the Company's convertible notes, compared to $1.1 million and $2.7 million in non-cash interest for the same period in 2009.

      Net loss attributed to Verenium for the quarter ended June 30, 2010 was $4.5 million compared to a net loss of $20.0 million for the same period in 2009, on a GAAP accounting basis. Adjusted for the non-cash impact of gains on debt extinguishment and gains and losses for fair value remeasurements related to the 8% and 9% convertible notes, the Company's non-GAAP pro-forma net loss for the quarter ended June 30, 2010 was $3.7 million compared to $12.5 million for the same period in the prior year. The Company believes that excluding the non-cash impact of these items provides a more consistent measure of operating results.  

      As of June 30, 2010, the Company had unrestricted cash and cash equivalents totaling approximately $16.5 million compared to $15.5 million at March 31, 2010 and $32.1 million as of December 31, 2009.  A significant portion of the decrease in cash and cash equivalents as compared to the end of fiscal 2009 is due to the deconsolidation of Vercipia cash and cash equivalents of approximately $7.2 million, based upon authoritative accounting guidance effective on January 1, 2010.  

      "Verenium had an impressive second quarter with good growth in total product revenues indicating that our newer enzyme products continue to gain traction in their respective target markets," said James E. Levine, Executive Vice President and Chief Financial Officer.  "We believe that following the close of the BP transaction, Verenium will have an even greater opportunity to maximize the potential of our existing commercial and development portfolio by investing strategically in areas such as manufacturing and R&D.  We also expect to have a greatly improved financial position providing a significant opportunity to create value for our shareholders."

      Financial Guidance

      The Company is providing the following financial guidance for its fiscal year ending December 31, 2010:

      • 2010 product revenue: $48 to $54 million
      • 2010 product gross margin: $16 to $18 million

      The Company expects to provide guidance for its fiscal year 2011 early next year.

      Unaudited Pro Forma Financial Statements

      In addition to its GAAP-based financial statements and supplemental non-GAAP pro forma financial information, the Company has also provided, in the attached tables, its unaudited pro forma financial statements as of June 30, 2010 and for the three and six months ended June 30, 2010 and 2009, giving effect to the proposed sale of the Company's biofuels business as if the sale had occurred at the beginning of each of the periods presented.

      About Verenium

      Verenium Corporation is a pioneer in the development and commercialization of high-performance enzymes for use in industrial processes.  Verenium currently sells enzymes developed using its R&D capabilities to industrial customers globally for use in markets including biofuels, animal health and oil seed processing. Verenium has built a world-class R&D organization renowned for its capabilities in the rapid screening, identification, and bioengineering of novel enzymes that act as catalysts for biochemical reactions. The company harnesses the power of nature and uses its unique, patented technology to create products that transform industries by maximizing efficiency while improving environmental performance. For more information on Verenium, visit http://www.verenium.com.

      Forward Looking Statements

      Statements in this press release that are not strictly historical are "forward-looking" and involve a high degree of risk and uncertainty.  These include, but are not limited to, statements related to the closing of the sale of the Company's biofuels business to BP, the Company's post-closing lines of business, operations, capabilities, commercialization activities, corporate partnerships, target markets and future financial performance, results and objectives, all of which are prospective.  Such statements are only predictions, and actual events or results may differ materially from those projected in such forward-looking statements.  Factors that could cause or contribute to the differences include, but are not limited to, the failure or inability of Verenium and/or BP to satisfy all closing conditions related to the sale of Verenium's biofuels business, risks associated with Verenium's strategic focus, risks associated with Verenium's technologies, risks associated with Verenium's ability to obtain additional capital to support its planned operations and financial obligations, risks associated with Verenium's dependence on patents and proprietary rights, risks associated with Verenium's protection and enforcement of its patents and proprietary rights, the commercial prospects of the industries in which Verenium operates and sells products, Verenium's dependence on manufacturing and/or license agreements, and its ability to achieve milestones under existing and future collaboration agreements, the ability of Verenium and its partners to commercialize its technologies and products (including by obtaining any required regulatory approvals) using Verenium's technologies and timing for launching any commercial products and projects, the ability of Verenium and its collaborators to market and sell any products that it or they commercialize, the development or availability of competitive products or technologies, the future ability of Verenium to enter into and/or maintain collaboration and joint venture agreements and licenses, , and risks and other uncertainties more fully described in the Company's filings with the Securities and Exchange Commission, including, but not limited to, the Company's annual report on Form 10-K for the year ended December 31, 2009 and any updates contained in its subsequently filed quarterly reports on Form 10-Q.  These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any intent or obligation to update these forward-looking statements.

      Contacts:


      Kelly Lindenboom

      Vice President, Corporate Communications

      617-674-5335

      [email protected]


      Sarah Carmody

      Manager, Corporate Communications

      617-674-5357

      [email protected]




      Verenium Corporation

      Consolidated Statements of Operations

      (unaudited, in thousands, except per share amounts)



      Three Months Ended June 30,


      Six Months Ended June 30,






      2010


      2009


      2010


      2009

      Revenues:








        Product

      $         13,290


      $         10,499


      $       24,852


      $       21,068

        Grant

      6,299


      4,474


      7,037


      7,032

        Collaborative  

      460


      1,318


      1,191


      2,582









      Total revenue

      20,049


      16,291


      33,080


      30,682

















      Operating expenses:








        Cost of product revenue

      8,830


      7,450


      15,346


      13,205

        Research and development

      12,975


      16,132


      29,974


      33,947

        Selling, general and administrative

      7,491


      10,865


      15,189


      20,037









      Total operating expenses

      29,296


      34,447


      60,509


      67,189









      Loss from operations

      (9,247)


      (18,156)


      (27,429)


      (36,507)









      Interest and other expense, net

      (2,127)


      (3,299)


      (4,107)


      (6,413)

      Gain on debt extinguishment

      -


      2,509


      598


      6,118

      Gain (loss) on net change in fair value
        of derivative assets and liabilities

      (786)


      (9,943)


      (718)


      3,366









      Net loss

      (12,160)


      (28,889)


      (31,656)


      (33,436)

      Loss attributed to non-controlling interest
        In consolidated entities

      7,675


      8,925


      15,175


      16,795









      Net loss attributed to Verenium

      $            (4,485)


      $          (19,964)


      $       (16,481)


      $       (16,641)









      Basic and diluted net loss per share

      $              (0.37)


      $              (2.65)


      $             (1.35)


      $           (2.48)









      Shares used in computing basic
        and diluted net loss per share

      12,273


      7,546


      12,165


      6,700













      Verenium Corporation

      Condensed Consolidated Balance Sheet Data

      (in thousands)


      June 30,


      December 31,


      2010


      2009






      (Unaudited)



      Cash, cash equivalents

      $          16,522


      $           32,055

      Accounts receivable, net

      6,829


      7,209

      Inventory, net

      2,868


      2,653

      Other current assets  

      3,884


      4,657

      Restricted cash

      10,709


      10,400

      Property and equipment, net

      103,448


      108,399

      Other noncurrent assets  

      2,003


      2,549





      Total assets  

      $        146,263


      $        167,922









      Current liabilities, excluding deferred revenue  

      $           18,412


      $           22,967

      Deferred revenue  

      1,598


      2,199

      Convertible notes, at carrying value  

      105,869


      105,756

      Long term deferred revenue

      1,368


      -

      Other long term liabilities  

      8,862


      6,798

      Stockholders' equity  

      10,154


      30,202





      Total liabilities, noncontrolling interests and
         stockholders' equity  

      $        146,263


      $        167,922




      Verenium Corporation

      Unaudited Supplemental and Non-GAAP Pro Forma Financial Information

      (in thousands, except per share amounts)


      The following unaudited supplemental and non-GAAP pro forma financial information is derived from the Company's  condensed consolidated financial statements for the three- and six-month periods ended June 30, 2010 and 2009, as reported under GAAP. The Company believes that such supplemental and non-GAAP financial information is helpful to understand the results of operations of the business.







      Product Gross Margin




      Three Months Ended June 30,


      Six Months Ended June 30,






      2010


      2009


      2010


      2009

























        Product revenues

      $     13,290


      $     10,499


      $         24,852


      $         21,068

        Cost of product revenues

      8,830


      7,450


      15,346


      13,205









        Product gross margin  

      $       4,460


      $       3,049


      $          9,506


      $          7,863



















      Non-GAAP Pro Forma Net Operating Expenses




      Three Months Ended June 30,


      Six Months Ended June 30,






      2010


      2009


      2010


      2009

























        Operating expenses (excluding  cost of product revenue)

      $        20,466


      $        26,997


      $       45,163


      $       53,984









        Adjustments:  








        Loss attributed to non-controlling interest in consolidated subsidiaries  

      (7,675)


      (8,925)


      (15,175)


      (16,795)









      Non-GAAP pro forma net operating expenses    

      $        12,791


      $        18,072


      $       29,988


      $       37,189














      Non-GAAP Pro Forma Net Loss




      Three Months Ended June 30,


      Six Months Ended June 30,






      2010


      2009


      2010


      2009

























      Net loss attributed to Verenium

      $      (4,485)


      $     (19,964)


      $       (16,481)


      $       (16,641)









      Adjustments:  








      Gain on debt extinguishment

      -


      (2,509)


      (598)


      (6,118)

      (Gain) loss on net change in fair value of
      derivative assets and liabilities

      786


      9,943


      718


      (3,366)









      Non-GAAP pro forma net loss  

      $       (3,699)


      $     (12,530)


      $       (16,361)


      $       (26,125)









      Non-GAAP pro forma net loss per share           

      $         (0.30)


      $            (1.66)


      $           (1.34)


      $           (3.90)












      Verenium Corporation

      Unaudited Pro Forma Condensed Consolidated Statement of Operations

      for the Three Months Ended June 30, 2010

      (in thousands, except per share amounts)



      The accompanying unaudited pro forma condensed consolidated statement of operations for the three months ended June 30, 2010 give effect to the sale of the Company's biofuels business (the "LC Business") as if it had been consummated at the beginning of the period presented.


      Historical


      Pro Forma
      Adjustments
      Adjustments
      Related to
      the Sale of
      LC Business


      Unaudited
      Pro Forma
      Statement of
      Operations


      Revenues:







        Product

      $         13,290


      $                  -


      $       13,290


        Grant

      6,299


      (6,299)


      -


        Collaborative  

      460


      (69)


      391









      Total revenue

      20,049


      (6,368)

      (a)

      13,681
















      Operating expenses:







        Cost of product revenue

      8,830


      -


      8,830


        Research and development

      12,975


      (11,784)

      (b)

      1,191


        Selling, general and administrative

      7,491


      (1,165)

      (c)

      6,326









      Total operating expenses

      29,296


      (12,949)


      16,347









      Loss from operations

      (9,247)


      6,581


      (2,666)









      Interest and other expense, net

      (2,127)


      -


      (2,127)


      Loss on net change in fair value of derivative
       assets and liabilities

      (786)


      -


      (786)









      Net loss

      (12,160)


      6,581


      (5,579)


      Loss attributed to non-controlling interest
        in consolidated entities

      7,675


      (7,675)

      (d)

      -









      Net loss attributed to Verenium

      $            (4,485)


      $            (1,094)


      $         (5,579)









      Basic and diluted net loss per share

      $              (0.37)


      $              (0.09)


      $             (0.45)









      Shares used in computing basic and diluted
        net loss per share

      12,273


      12,273


      12,273












      Verenium Corporation

      Unaudited Pro Forma Condensed Consolidated Statement of Operations for the

      Six Months Ended June 30, 2010

      (in thousands, except per share amounts)


      The accompanying unaudited pro forma condensed consolidated statement of operations for the six months ended June 30, 2010 give effect to the sale of the Company's biofuels business (the "LC Business") as if it had been consummated at the beginning of the period presented.


      Historical


      Pro Forma
      Adjustments
      Adjustments
      Related to
      the Sale of
      LC Business


      Unaudited
      Pro Forma
      Statement of
      Operations


      Revenues:







        Product

      $          24,852


      $                 -


      $       24,852


        Grant

      7,037


      (7,037)


      -


        Collaborative  

      1,191


      (139)


      1,052









      Total revenue

      33,080


      (7,176)

      (a)

      25,904
















      Operating expenses:







        Cost of product revenue

      15,346


      -


      15,346


        Research and development

      29,974


      (27,385)

      (b)

      2,589


        Selling, general and administrative

      15,189


      (2,185)

      (c)

      13,004









      Total operating expenses

      60,509


      (29,570)


      30,939









      Loss from operations

      (27,429)


      22,394


      (5,035)









      Interest and other expense, net

      (4,107)


      -


      (4,107)


      Gain on debt extinguishment

      598


      -


      598


      Loss on net change in fair value of derivative
        assets and liabilities

      (718)


      -


      (718)









      Net loss

      (31,656)


      22,394


      (9,262)


      Loss attributed to non-controlling interest
        in consolidated entities

      15,175


      (15,175)

      (d)

      -









      Net loss attributed to Verenium

      $          (16,481)


      $            7,219


      $        (9,262)









      Basic and diluted net loss per share

      $              (1.35)


      $            (0.59)


      $             (0.76)









      Shares used in computing basic and
        diluted net loss per share

      12,165


      12,165


      12,165












      Verenium Corporation

      Unaudited Pro Forma Condensed Consolidated Statement of Operations for the

      Three Months Ended June 30, 2009

      (in thousands, except per share amounts)


      The accompanying unaudited pro forma condensed consolidated statement of operations for the three months ended June 30, 2009 give effect to the sale of the Company's biofuels business (the "LC Business") as if it had been consummated at the beginning of the period presented.


      Historical


      Pro Forma
      Adjustments
      Adjustments
      Related to the
      Sale of LC
      Business


      Unaudited
      Pro Forma
      Statement of
      Operations


      Revenues:







        Product

      $          10,499


      $                 -


      $       10,499


        Grant

      4,474


      (4,474)


      -


        Collaborative  

      1,318


      (69)


      1,249









      Total revenue

      16,291


      (4,543)

      (a)

      11,748
















      Operating expenses:







        Cost of product revenue

      7,450


      -


      7,450


        Research and development

      16,132


      (14,755)

      (b)

      1,377


        Selling, general and administrative

      10,865


      (2,773)

      (c)

      8,092









      Total operating expenses

      34,447


      (17,528)


      16,919









      Loss from operations

      (18,156)


      12,985


      (5,171)









      Interest and other expense, net

      (3,299)


      -


      (3,299)


      Gain on debt extinguishment

      2,509


      -


      2,509


      Loss on net change in fair value of derivative
        assets and liabilities

      (9,943)


      -


      (9,943)









      Net loss

      (28,889)


      12,985


      (15,904)


      Loss attributed to non-controlling interest
       in consolidated entities

      8,925


      (8,925)

      (d)

      -









      Net loss attributed to Verenium

      $          (19,964)


      $            4,060


      $       (15,904)









      Basic and diluted net loss per share

      $              (2.65)


      $              0.54


      $             (2.11)









      Shares used in computing basic and diluted
        net loss per share

      7,546


      7,546


      7,546












      Verenium Corporation

      Unaudited Pro Forma Condensed Consolidated Statement of Operations for the

      Six Months Ended June 30, 2009

      (in thousands, except per share amounts)


      The accompanying unaudited pro forma condensed consolidated statement of operations for the six months ended June 30, 2009 give effect to the sale of the Company's biofuels business (the "LC Business") as if it had been consummated at the beginning of the period presented.


      Historical


      Pro Forma
      Adjustments
      Adjustments
      Related to the
      Sale of LC
      Business


      Unaudited
      Pro Forma
      Statement of
      Operations


      Revenues:







        Product

      $         21,068


      $                  -


      $       21,068


        Grant

      7,032


      (7,010)


      22


        Collaborative  

      2,582


      (137)


      2,445









      Total revenue

      30,682


      (7,147)

      (a)

      23,535
















      Operating expenses:







        Cost of product revenue

      13,205


      -


      13,205


        Research and development

      33,947


      (30,888)

      (b)

      3,059


        Selling, general and administrative

      20,037


      (5,327)

      (c)

      14,710









      Total operating expenses

      67,189


      (36,215)


      30,974









      Loss from operations

      (36,507)


      29,068


      (7,439)









      Interest and other expense, net

      (6,413)


      -


      (6,413)


      Gain on debt extinguishment

      6,118


      -


      6,118


      Gain on net change in fair value of derivative
        assets and liabilities

      3,366


      -


      3,366









      Net loss

      (33,436)


      29,068


      (4,368)


      Loss attributed to non-controlling interest
            in consolidated entities

      16,795


      (16,795)

      (d)

      -









      Net loss attributed to Verenium

      $          (16,641)


      $           12,273


      $         (4,368)









      Basic and diluted net loss per share

      $              (2.48)


      $              (1.83)


      $             (0.65)









      Shares used in computing basic and diluted net loss
        per share

      6,700


      6,700


      6,700












      Verenium Corporation

      Unaudited Pro Forma Condensed Consolidated Balance Sheet

      As of June 30, 2010

      (in thousands)


      The accompanying unaudited pro forma condensed consolidated balance sheet as of June 30, 2010 gives effect to the sale of the LC Business as if it had been consummated as of June 30, 2010, including the impact of the estimated net cash proceeds related to the disposition.


      Historical


      Pro Forma
      Adjustments
      Adjustments Related
      to the Sale of
      the  LC Business


      Unaudited
      Pro Forma
      Balance Sheet








      (Unaudited)





      Cash, cash equivalents

      $          16,522


      $         104,378

      (e)

      $     120,900

      Accounts receivable, net

      6,829


      (129)

      (f)

      6,700

      Inventory, net

      2,868


      (65)

      (f)

      2,803

      Other current assets

      3,884


      (1,856)

      (f)

      2,028

      Restricted cash

      10,709


      (10,709)

      (e)

      -

      Property and equipment, net  

      103,448


      (101,237)

      (f)

      2,211

      Other noncurrent assets  

      2,003


      (345)

      (f)

      1,658







      Total assets  

      $        146,263


      $           (9,963)


      $      136,300













      Current liabilities, excluding deferred revenue  

      $          18,412


      $            (6,300)

      (f)

      $        12,112

      Deferred revenue  

      1,598


      (278)

      (f)

      1,320

      Convertible notes, at carrying value  

      105,869


      -


      105,869

      Long term deferred revenue

      1,368


      (917)

      (f)

      451

      Other long term liabilities  

      8,862


      (8,206)

      (f)

      656

      Stockholders' equity  

      10,154


      5,738

      (g)

      15,892







      Total liabilities, noncontrolling interests and
         stockholders' equity  

      $        146,263


      $          (9,963)


      $       136,300










      Verenium Corporation

      Footnotes to Unaudited Pro Forma Condensed

      Consolidated Financial Statements


      The historical financial information on which the pro forma financial statements are based is included in Verenium's Quarterly Report on Form 10-Q for the three and six month periods ended June 30, 2010 and 2009, which the Company intends to file on August 9, 2010. The pro forma consolidated financial statements and the notes thereto should be read in conjunction with these historical consolidated financial statements.


      The unaudited pro forma consolidated financial statements are presented for illustrative purposes only and are subject to a number of assumptions which may not be indicative of the results of operations that would have occurred had the disposition been completed at the dates indicated or what the results will be for any future periods. The unaudited pro forma consolidated statements of operations do not include the gain or loss attributed to the sale of the LC Business if the transaction was completed at the beginning of the periods presented.


      (a) This adjustment is recorded to remove LC Business revenue from the Company's results from continuing operations, related to collaboration, grants and license agreements that have been assumed by BP.

      (b) This adjustment is recorded to remove LC Business research and development expenses from the Company's results from continuing operations. Such expenses consist of including both direct project costs and allocated expenses related to the LC Business which are being assumed by BP, including all costs related to the San Diego, California facility leases.

      (c) This adjustment is recorded to remove LC Business selling, general and administrative expenses from the Company's results from continuing operations. The pro forma expenses include non-cash stock-based compensation of $0.3 million and $0.7 million for the three and six months ended June 30, 2010 and $2.3 million and $3.3 million for the three and six months ended June 30, 2009.

      (d) This adjustment is recorded to remove the losses from the Company's variable interest entities ("VIE"), Galaxy and Vercipia, that were historically attributed to BP, the other party to the VIE.

      (e) This adjustment is recorded to reflect net cash that the Company estimates it would have received as consideration for the sale of the LC Business if the transaction was completed on June 30, 2010. The purchase price of $98.3 million has been reduced by estimated transaction-related expenses, as well as the working capital adjustment at June 30, 2010, as required under the Asset Purchase Agreement. This adjustment also reflects the release of $10.7 million in restricted cash as of June 30, 2010 used to secure the outstanding letter of credit under the San Diego, California facility leases, as such leases are being assumed by BP.

      (f) These adjustments are recorded to reflect the disposition of the LC Business assets and liabilities as of June 30, 2010 included in the Company's historical condensed consolidated financial statements.

      (g) This adjustment includes the gain recorded on the sale of the LC Business, assuming the transaction closed on June 30, 2010, and the amount recorded to remove the non-controlling interest in the Company's VIE, Galaxy, which BP is acquiring in the transaction.




      SOURCE Verenium Corporation

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.